FM
TRIB

Fondren Management’s Trinity Biotech TRIB Stock Holding History

Fondren Management’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1,533
Closed -$253K – 54
2020
Q1 		$253K Sell
1,533
-4,724
-75% -$742K 0.64% 41
2019
Q4 		$970K Buy
6,257
+1,457
+30% +$208K 0.99% 27
2019
Q3 		$871K Buy
4,800
+2,267
+89% +$591K 0.72% 40
2019
Q2 		$627K Buy
2,533
+84
+3% +$30K 0.6% 44
2019
Q1 		$1.05M Buy
2,449
+204
+9% +$84.1K 0.83% 30
2018
Q4 		$771K Buy
2,245
+1,278
+132% +$592K 1.01% 26
2018
Q3 		$580K Buy
967
+67
+7% +$43.7K 0.52% 40
2018
Q2 		$675K Buy
900
+233
+35% +$168K 0.52% 51
2018
Q1 		$515K Hold
667
– – 0.65% 30
2017
Q4 		$510K Buy
+667
New +$516K 0.36% 38
2017
Q3 		– Sell
-600
Closed -$540K – 65
2017
Q2 		$540K Sell
600
-2,133
-78% -$1.81M 0.59% 26
2017
Q1 		$2.44M Buy
2,733
+600
+28% +$563K 2.62% 12
2016
Q4 		$2.21M Buy
+2,133
New +$2.2M 1.58% 17

Other funds holding TRIB

SCM
Stonehill Capital Management New York $350M AUM 73.6% 1-Year Est. Return
HAIM
Hunter Associates Investment Management Pittsburgh, Pennsylvania $868M AUM 32.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $2.25B AUM 44.61% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return

Fondren Management's TRIB Position: Q2 2020 in Review

Fondren Management sold out of Trinity Biotech (TRIB) in Q2 2020, closing a stake of 1,533 shares — an estimated $253K sold.

Fondren Management first reported a position in TRIB in Q4 2016 and held it in 13 quarters. The position peaked at $2.44M in Q1 2017. 26 funds tracked by Wall St. Rank hold TRIB as of Q2 2020.

  • Fondren Management reported no remaining Trinity Biotech position as of Q2 2020 after selling out during the quarter.
  • Fondren Management sold 1,533 Trinity Biotech shares in Q2 2020, an estimated $253K.
  • Fondren Management first reported a position in Trinity Biotech in Q4 2016 and held it in 13 quarters.
  • Fondren Management's Trinity Biotech position peaked at $2.44M in Q1 2017.
  • 26 funds tracked by Wall St. Rank held Trinity Biotech as of Q2 2020.

Based on Fondren Management's 13F filing for Q2 2020, filed 14 Aug 2020.